Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tideglusib in congenital myotonic dystrophy
NCT03692312Phase 3Completed
- Sponsor
- AMO Pharma Limited
- Start
- Mar 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in congenital myotonic dystrophy (CDM) comparing Tideglusib with Placebo (2 arms). Primary endpoint: Clinician-Completed Congenital DM1 Rating Scale at 20 weeks. Started Mar 2021; status: completed.
02
Drugs
tideglusib
03
Conditions
congenital myotonic dystrophy (CDM)
Beyond the preview
Go deeper on NCT03692312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692312.